menu search

Scancell makes strong progress with lead immunotherapy assets

Key highlights for biotech group Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s financial year ending April 30 included a positive data reading arising...

October 31, 2023, 4:48 am

Sutro biopharma announces presentation of data for luveltamab tazevibulin (luvelta) from the phase 1 dose-expansion study in endometrial cancers at esmo 2023

– Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial ca...

October 22, 2023, 8:25 am

Sellas life sciences to present final data from phase 1/2 study of galinpepimut-s in combination with keytruda® (pembrolizumab) in patients with wt1+ platinum-resistant advanced ovarian cancer at the

NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical b...

October 17, 2023, 8:45 am

Regeneron to showcase progress from innovative oncology portfolio in several difficult-to-treat cancers at esmo

Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be ...

October 15, 2023, 10:05 pm

Sutro biopharma: luvelta data for endometrial cancer treatment approaching

Sutro Biopharma is advancing its lead candidate, luvelta, for the treatment of various types of cancer, with a focus on ...

October 9, 2023, 9:48 am

Verastem: signs of life for a beaten-down equity

Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main candidate being avutometinib. Avutometinib is b...

October 4, 2023, 9:00 pm

Exelixis to license insilico ai-designed cancer drug

Exelixis Inc. EXEL, -0.54% is licensing the global rights to develop and commercialize an investigational cancer treatment that was derived from Insil...

September 12, 2023, 8:40 am

Nuvectis: early stage company that's low on cash

Nuvectis is developing precision medicines for cancer patients, with lead asset NXP800 targeting ARID1a-mutated ...

September 6, 2023, 8:03 am

Why novocure stock fell 24.4% this week

On Monday, Novocure announced a key phase 3 trial evaluating its Tumor Treating Fields (TTFields) therapy in treating platinum-resistant ...

August 31, 2023, 6:52 pm

23andme stock rallies more than 23% after genetics company gets ok to report more cancer risks

Shares of 23andMe Holding Co. ME, -4.35% jumped 23% in the extended session Thursday after the genetics and biopharmaceutical company said that the U....

August 31, 2023, 5:49 pm

23andme granted new fda clearance to report additional brca variants

510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ...

August 31, 2023, 5:28 pm

Is novocure's stock headed for a free fall?

NovoCure's treatment for ovarian cancer failed to prove it was effective in a late-stage trial. It's a ...

August 31, 2023, 9:55 am

Immunogen: takeda swoops for slice of elahere - adding to valuation uncertainty?

Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuxi...

August 29, 2023, 1:45 pm

Novocure shares plunge after its ovarian cancer treatment fails to meet goal

Novocure (NVCR) shares plunged 37.5% on Monday after the provider of cancer-fighting treatments reported a Phase 3 trial of its Tumor Treating Fields ...

August 28, 2023, 5:25 pm

Why is novocure (nvcr) stock down 30% today?

Shares of innovative biotechnology firm Novocure (NASDAQ: NVCR ) cratered badly, losing 30% on Monday morning before fading even further in the early ...

August 28, 2023, 2:53 pm

Why novocure stock is crashing today

NovoCure's tumor treating fields therapy didn't meet the primary endpoint in a phase 3 study targeting ovarian...

August 28, 2023, 12:21 pm

Novocure stock plummets after phase 3 cancer trial fails to reach desired endpoint

Novocure (NASDAQ:NVCR) shares are down nearly a third Monday after a Phase 3 study of its Tumor Treating Fields therapy was reported to have failed. ...

August 28, 2023, 12:04 pm

Novocure shares plunge after ovarian cancer study failure

Shares of Novocure Ltd. NVCR, -0.77% dropped 37% premarket on Monday after the Swiss oncology company said a late-stage trial of Tumor Treating Fields...

August 28, 2023, 8:34 am

Novocure's cancer therapy fails to meet main goal in late-stage trial

Novocure said on Monday its therapy failed in a late-stage trial to meet the main goal of improving survival rates in patients with a type of ...

August 28, 2023, 7:35 am

Immunogen stock jumps after licensing deal with japan's takeda pharmaceutical

Shares of ImmunoGen Inc. IMGN, +1.45% jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with...

August 28, 2023, 6:50 am


Search within

Pages Search Results: